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Background: The spread of drug resistance in malaria parasites and the limited number of effective drugs for
treatment indicates the need for new anti-malarial compounds. Current assays evaluating drugs against Plasmodium
falciparum require expensive materials and equipment, thus limiting the search for new drugs, particularly in
developing countries. This study describes an inexpensive procedure that is based on the advantage of a positive
correlation between the haemozoin level of infected erythrocytes and parasite load.
Methods: The relationship between parasitaemia and the haemozoin level of infected erythrocytes was
investigated after converting haemozoin into monomeric haem. The 50% inhibitory concentration (IC50) values of
chloroquine, quinine, artemisinin, quinidine and clotrimazole against P. falciparum K1 and 9A strains were
determined using the novel assay method.
Results: The haemozoin of parasites was extracted and converted into monomeric haem, allowing the use of a
colorimeter to efficiently and rapidly measure the growth of the parasites. There was a strong and direct linear
relationship between the absorbance of haem converted from haemozoin and the percentage of the parasite
(R2 = 0.9929). Furthermore, the IC50 values of drugs were within the range of the values previously reported.
Conclusion: The haemozoin-based colorimetric assay can be considered as an alternative, simple, robust,
inexpensive and convenient method, making it applicable in developing countries.
Keywords: Anti-malarial, Assay, Haemozoin, MalariaBackground
Malaria is more than just a problem for tropical coun-
tries, it also is a major global public health concern. An-
nually, there are approximately 300 million new malaria
infections and millions of deaths worldwide due to mal-
aria [1,2]. Because a vaccine for malaria is not available,
chemotherapy is the main treatment. However, the rapid
spread of resistance to current quinoline anti-malarials
has made malaria a major global and important problem.
In addition, artemisinin, from a Chinese herb (Qin-
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reproduction in any medium, provided the ormore than a thousand years, is now considered an essen-
tial component of artemisinin-based combination ther-
apy against drug-resistant malaria [3,4]. However, the
malaria parasites have recently been found to be resist-
ant to artemisinin [5-7]. The alarming spread of drug re-
sistance and the limited number of effective drugs for
treatment indicates how important it is to find new anti-
malarial compounds.
For decades, the anti-malarial activity of a drug has
been measured in vitro by quantifying the uptake of
radioactive substrates by a parasite as a measure of
growth and viability in the presence of the test drug
[8,9]. Although several in vitro methods exist, the 3H-
hypoxanthine method [8] is a popular test for novel
anti-malarial drugs, but it is labelled with radiation that
presents a potential risk to safety, and it relies ond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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step procedures that become increasingly problematic
and impractical when the incidence of testing is
increased. The other methods, including the PicoGreen
[10,11] and the SYBR Green I [12,13] methods, are also
considered to be expensive approaches regarding equip-
ment and chemicals. In addition, there are other meth-
ods that are based on enzymatic reaction and/or
antibodies that specifically detect the presence of
histidine-rich protein II or parasite lactate dehydrogen-
ase [14-16]. However, these methods involve multiple
complex steps that are too expensive for developing
countries, which makes them ill suited for screening po-
tential anti-plasmodial drugs.
During the development and proliferation stage in host
erythrocytes, the malaria parasites degrade haemoglobin
for use as a major source of amino acids. This is accom-
panied by the release of free haem. With haem as a pros-
thetic group of haemoglobin, the iron is in the ferrous
state, but free haem loses one electron and assumes the
ferric state. This ferric haem could be oxidatively active
and toxic to both the host cells and malaria parasites,
and can even cause parasite death. Moreover, due to the
absence of haem oxygenase, the parasite is unable to
cleave haem into an open-chain free haem, which is ne-
cessary for cellular excretion [17]. To protect itself, it is
necessary for the parasite to convert haem to non-toxic
metabolites. Principally, the parasite detoxifies free haem
via neutralization with histidine-rich protein 2 [18,19]
and degradation with reduced glutathione [20,21], but
mostly with crystallization into haemozoin, which is a
water-insoluble malarial pigment produced in the food
vacuole [19,22]. Therefore, a simple and inexpensive
in vitro assay was developed based on the colorimetric
quantification of haemozoin in infected red blood cells
to evaluate the anti-malarial activity of drugs.
Methods
Materials
Chloroquine diphosphate, quinine sulphate, primaquine,
clotrimazole, haemin chloride (haem), RPMI 1640
medium, hypoxanthine, and gentamycin were purchased
from Sigma Aldrich Chemical Company (Tokyo, Japan).
Albumax II (Gibco), and the other chemicals used in
the present study were of a high grade. Plasmodium
falciparum K1 (chloroquine resistant) and 3D7-9A
(chloroquine susceptible) strains [23] were provided
from Dr Osamu Kaneko and Dr Shusuke Nakazawa,
respectively, from the Institute of Tropical Medicine,
Nagasaki University, Japan.
Plasmodium cultivation
Plasmodium falciparum K1 and 9A strains were main-
tained in vitro with continuous culture according to apreviously described method with a slight modification
[24]. The culture medium consisted of RPMI 1640 sup-
plemented with 0.025 mg/ml gentamicin, 0.01 mM
hypoxanthine, 23.8 mM NaHCO3, 11 mM glucose and
0.5% albumax II, and adjusted to a pH of 7.3 to 7.4. The
parasite was cultured and maintained in a tissue culture
flask with complete culture medium containing 5%
human erythrocytes. The parasite density was main-
tained at about 1.5% parasitaemia under an atmosphere
of an AnaeroPack sachet (Mitsubishi Gas Chemical
Company Inc, Tokyo, Japan) to create 20% CO2 and re-
move O2 (<0.1%) 37°C [25]. Every two days, infected ery-
throcytes were transferred into fresh medium containing
5% human erythrocyte. The level of parasitaemia was
determined by light microscopy on a Giemsa-stained
thin blood smear, and parasitized erythrocytes were
diluted when parasitaemia was higher than 5% in ery-
throcytes contained at 5% in culture medium, in order
to lower parasitaemia and allow continuous growth.
Parasite culture was diluted with fresh uninfected ery-
throcytes and culture medium to achieve a starting para-
sitaemia of 2% and a haematocrit of 5%. This final
parasite culture was immediately used for anti-malarial
assay.
The relationship between parasitaemia and haemozoin
level
A culture of the P. falciparum K1 strain was serially
diluted with uninfected erythrocytes in complete medium
to yield a haematocrit of 5% and parasitaemia ranging
from 0 to 10%. The serial culture containing 200 μl was
prepared independently in triplicate in microtubes, fol-
lowed by the addition of 800 μl of 2.5% sodium dodecyl
sulphate in 0.1 M sodium bicarbonate pH 8.8, then the
samples were mixed at room temperature for 15 min.
After centrifugation at 13,000 rpm for 10 min, the super-
natant was removed. The pellet was washed twice with
800 μl of 2.5% sodium dodecyl sulphate in 0.1 M sodium
bicarbonate (pH 8.8), then 200 μl of 5% sodium dodecyl
sulphate was added to 50 mM NaOH to convert the hae-
mozoin into haem. After incubation at room temperature
for 30 min, the sample (200 μl) was transferred to a 96-
well microplate and scanned at 405/750 nm (A405 nm
minus A750 nm) using an IMark microplate reader (Bio-
Rad). After the background absorbance of haemozoin
was purified of uninfected erythrocytes (5% haematocrit)
then subtracted, the amount of haemozoin in the
infected erythrocytes was presented as the absorbance at
405/750 nm and then plotted against parasitaemia.
Evaluating the anti-malarial activity of drugs using the
haemozoin-based spectrophotometric method
The P. falciparum K1 and 9A strains were used to evalu-















Figure 1 The linear relationship between the haemozoin level
of a parasite and parasitaemia. Haemozoin concentration of
infected erythrocytes is presented by the absorbance at 405/750 nm
of monomeric haem after conversion from haemozoin using an
NaOH solution. Absorption values (means ± standard errors of
triplicate wells) are plotted against parasitaemia. A well correlated,
















Figure 2 Representative dose responses for chloroquine (CQ),
artemisinin (ART) and quinine against the Plasmodium
falciparum K1 strain. Parasite growth after incubation of parasitized
erythrocytes for 72 hr with a drug was measured using a
haemozoin-based colorimetric method. The symbols and error bars
are the average absorption values at 405/750 nm and standard
deviations in triplicate, respectively. The sigmoidal dose response
model with a variable slope is the best fit to the data.
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the haemozoin-based spectrophotometric method.
Stocks of drugs were prepared in dimethyl sulphoxide or
phosphate buffer saline (for chloroquine) and were then
serially diluted with complete culture medium. To each
well of a microplate, 10 μl of serially diluted drug solu-
tion was added into 200 μl of final asynchronous para-
site culture. Dimethyl sulphoxide or phosphate buffer
saline were also tested by adding a similar amount to
control wells. The microplates were cultured 72 hr
under the conditions described above. The haemozoin of
infected erythrocytes was extracted, purified, and quanti-
fied, as described above. The 50% inhibitory concentra-
tion (IC50) value was calculated by non-linear fitting of
the absorbance at 405/750 nm against the logarithm of
the drug concentration using the GraphPad Prism 5
(GraphPad Software, Inc., San Diego, CA, USA). Sig-
moidal doses with variable slope models were used with
the following equation:
y ¼ minþ max min
1þ 10 logIC50xf gHill slopeð Þ
where y is the absorbance at 405/750 nm; x is the loga-
rithm of the drug concentration, min is the absorbance
at 405/750 nm measured at time zero (starting point of
assay), and max is the maximal absorbance of a particu-
lar drug. The Hill slope is the steepness of the curve.
The logarithm of the concentration at zero was defined
at 2 log lower than the lowest concentration of a par-
ticular drug.
Results and discussion
Relationship between the absorbance of the haem
content of haemozoin and parasitaemia
The relationship between the haemozoin amount in a
parasitized erythrocyte and parasitaemia was revealed by
measuring the absorbance of the haem content of the hae-
mozoin obtained from the parasitized erythrocytes after
degradation to monomer haem. As shown in Figure 1, the
absorption of converted haem showed a direct and linear
correlation with the level of parasitaemia. Low and unsyn-
chronized parasitaemia (about 1%) could be detected using
this haemozoin-based colorimetric method. The results in-
dicate that this novel assay of parasites is applicable for
monitoring parasite growth and for screening new anti-
malarial compounds.
Haemozoin-based colorimetric assay to determine the
IC50 values
The IC50 values of some anti-malarial drugs were deter-
mined with a dose-response experiment using a
haemozoin-based colorimetric assay. The result showed
that increasing the concentration of anti-malarial drugsresulted in a decreased absorbance at 405/750 nm (Figure 2).
The data was best fitted by a typical sigmoidal dose-
response model with a variable slope (four parameters) that
agreed well with previous reports [26,27].
Table 1 summarizes the results of the assay to deter-
mine IC50 using the haemozoin-based colorimetric
method. The P. falciparum K1 strain was primarily
observed for quinine, chloroquine, clotrimazole, pyri-
methamine and artemisinin, with IC50 values of 0.258,
Table 1 In vitro anti-malarial activities of drugs against
chloroquine-susceptible (9A) and -resistant (K1) strains of
Plasmodium falciparum
Drugs Mean IC50 and 95% CI (μM)
P. falciparum K1 strain P. falciparum 9A strain
Quinine 0.258 (0.242 - 0.275) 0.398 (0.307 - 0.516)
Chloroquine 0.873 (0.824 - 0.926) 0.132 (0.082 - 0.211)
Clotrimazole 0.805 (0.689 - 0.939) 1.67 (1.18 – 2.37)
Pyrimethamine 23.03 (18.36 - 28.90) Not done
Artemisinin 0.139 (0.124 - 0.155) 0.483 (0.376 - 0.622)
Parasitized red blood cells were incubated with different concentrations of
drugs for 72 hr and parasite growth was evaluated using the haemozoin-
based colorimetric method. The IC50 and its 95% confidence interval (95% CI)
were calculated from the concentration-response curve of the haemozoin level
vs the log concentration of a drug.
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P. falciparum 9A strain, pyrimethamine was not evalu-
ated, and the IC50 values were 0.398, 0.132, 1.67 and
0.483 μM in succession for quinine, chloroquine, clotri-
mazole and artemisinin, respectively. The IC50 values for
quinine, chloroquine, clotrimazole, and pyrimethamine
were in a range that was similar to those observed in
previous reports [28,29]. On the other hand, the IC50
values for artemisinine were higher than previous
reports, probably due to asynchronous cultures, ring
stage-specific target of artemisinine, accumulation of
released hemozoin in the continuous cultures, or several
rounds of continuous cultures and cloning of parasite
strains in our laboratories. Therefore, further studies are
required to compare the novel assay with recent devel-
oped methods to validate the accuracy in the screening
new antimalarial compounds [30]. Another limitation of
the novel method is that it is not easily adaptable for a
high throughput screening of anti-malarial drug candi-
dates, which is under-developed using 96-well filter
plates [31].
In recent years, the number of laboratories, diagnosis
centres and research institutes has risen in developing
countries. However, most of them lack the modern
equipment and expensive chemicals to apply new meth-
ods for screening anti-malarial candidates. In addition,
some methods have potential risks of toxicity, so it is
prudent to wear disposable gloves at all times when pro-
ceeding. Another obstacle is that many laboratories lack
the facilities to treat toxic contamination before the
toxin is discarded in the environment. The novel anti-
malarial assay is safe, non-expensive and easy to apply in
laboratories.
Conclusions
The standard curve obtained in this study was strongly
linear between the absorbance of monomeric haem
converted from haemozoin and the percentage ofparasitaemia. The IC50 values of chloroquine and quin-
ine obtained from the haemozoin-based colorimetric
method are similar to other methods. Even though this
report describes specific conditions, the current experi-
ment has introduced an assay that is adaptable to a wide
range of conditions. The results also show that using this
method has several advantages over using current meth-
ods. First, the method is fast and is based on a simple
technique that uses a microplate reader, which is avail-
able in most laboratories. Second, the assay is based on
inexpensive chemicals with no requirement of cold
storage. Last but not least, the assay of the inhibition
of P. falciparum growth using a haemozoin-based colori-
metric method is feasible, reproducible, non-toxic, and
more convenient than other assays, which makes it par-
ticularly useful for developing countries in the screening
of novel anti-plasmodials, as a useful high throughput
screening method for anti-malarial drug candidates.
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